Definitive Healthcare (NASDAQ:DH) Cut to Hold at Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

DH has been the subject of a number of other research reports. Zacks Research upgraded Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Bank of America restated an “underperform” rating and issued a $0.70 target price on shares of Definitive Healthcare in a report on Monday, June 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Wednesday, June 3rd. Barclays reduced their target price on Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a report on Monday, March 30th. Finally, Robert W. Baird set a $1.10 price target on Definitive Healthcare in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have issued a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $2.47.

Definitive Healthcare Stock Down 7.6%

NASDAQ DH opened at $0.76 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75. The company’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $1.32. Definitive Healthcare has a 12 month low of $0.62 and a 12 month high of $4.70. The company has a market capitalization of $80.09 million, a P/E ratio of -0.47, a PEG ratio of 10.94 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $55.93 million during the quarter, compared to analyst estimates of $55.02 million. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Equities research analysts expect that Definitive Healthcare will post 0.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DH. Goldman Sachs Group Inc. raised its stake in Definitive Healthcare by 564.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after purchasing an additional 7,404,363 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Definitive Healthcare by 1.6% in the third quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock valued at $8,417,000 after purchasing an additional 33,612 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Definitive Healthcare by 11.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock worth $4,937,000 after buying an additional 127,055 shares during the period. Bank of America Corp DE boosted its position in shares of Definitive Healthcare by 23.7% in the second quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock worth $3,001,000 after buying an additional 147,599 shares during the period. Finally, Inspire Investing LLC grew its holdings in shares of Definitive Healthcare by 505.7% during the fourth quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock valued at $2,006,000 after buying an additional 583,562 shares in the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.